The guidelines support use of PPIs, dietary therapy, and biologics for EoE, and stress the importance of addressing both the inflammatory and fibrostenotic aspects of the disease.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...

Nevertheless, classification criteria often seem to be arbitrarily chosen, and the nomenclature that is used to describe their features often varies. Consequently, communication among ...

Background: Rising use of sunscreen products has led to increased reporting of adverse reactions to sunscreens. Objective: To investigate possible photoallergic reactions in patients who ...

Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...

1 The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China A 42 year-old ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...